Supernus Pharmaceuticals, Inc.
A maker of brain and nervous-system medicines, Supernus develops and sells branded treatments for ADHD, Parkinson's disease, epilepsy, and postpartum depression—brands like Qelbree, GOCOVRI, Trokendi XR, and ZURZUVAE. It began in 2005 as a spin-out of Shire Laboratories, founded by Jack Khattar, who then bought the very business he had led. Its name comes from Latin for "from above," a fitting label for a company born out of the lab it once ran.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Millennium Management LLC | 13G/APassive | 6.6% | 3.85M | Aug 6, 2026 |
| Millennium Group Management LLC | 13G/APassive | 6.6% | 3.85M | Aug 6, 2026 |
| Israel A. Englander | 13G/APassive | 6.6% | 3.85M | Aug 6, 2026 |
| Integrated Core Strategies (US) LLC | 13G/APassive | 6.2% | 3.61M | Aug 6, 2026 |
| Vanguard Capital Management | 13GPassive | 5.03% | 2.90M | Apr 30, 2026 |
| Vanguard Portfolio Management | 13GPassive | 5.66% | 3.26M | Apr 29, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| Armistice Capital, LLC | 13G/APassive | 4.82% | 2.76M | Feb 17, 2026 |
| Steven Boyd | 13G/APassive | 4.82% | 2.76M | Feb 17, 2026 |
| Dimensional Fund Advisors LP | 13G/APassive | 4.7% | 2.71M | Jan 21, 2026 |